Immunovia successfully develops assays to measure targeted proteins for its next-generation pancreatic cancer test – moving forward towards model-development study

Posted on by

LUND, Sweden, April 9, 2024 /PRNewswire/ — Immunovia (NASDAQ: IMMNOV) (STO: IMMNOV), the diagnostics company with the mission to increase pancreatic cancer survival rates through early detection, announces today that the company has successfully developed accurate and precise assays to…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.